| ²é¿´: 2324 | »Ø¸´: 16 | ||
| µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû | ||
kdl0721½ð³æ (ÖøÃûдÊÖ)
|
[ÇóÖú]
ÇóIbrutinib Ò»¸ö¢óÆÚÁÙ´²ÊÔÑéºÍÊÔÑéÊý¾Ý¡¢½á¹û ÒÑÓÐ2È˲ÎÓë
|
|
|
ÊÔÑéÃû³Æ£º A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (RESONATE™ ![]() ÊÔÑéÄÚÈÝ£ºhttp://www.clinicaltrials.gov/show/NCT01578707 Çó³æÓѰïæ²éһϸÃÊÔÑé¹ý³ÌºÍ½á¹û¡£Ð»Ð»£¡ |
» ²ÂÄãϲ»¶
ҩѧ »¯Ñ§ ÉúÎïѧ ÉúÎïÓëÒ½Ò© ºÓÄÏʦ·¶´óѧ¿¹²¡¶¾ÐÔ´«È¾²¡´´ÐÂÒ©ÎïÈ«¹úÖØµãʵÑéÊÒ
ÒѾÓÐ0È˻ظ´
½Î÷
ÒѾÓÐ13È˻ظ´
Ò©ÀíѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ97È˻ظ´
½Î÷¿Æ¼¼Ê¦·¶´óѧ086ÉúÎïÓëÒ½Ò©
ÒѾÓÐ15È˻ظ´
½¥¶³Ö¢²¡Òò¼°¸ÉÔ¤·½°¸È«Ð½âÎö
ÒѾÓÐ2È˻ظ´
ÇóÖúÓÃ΢Æ×Êý¾Ý¿â²éѯÏà¹ØÎÄÏ×ÐÅÏ¢£¬·Ç³£¸Ðл
ÒѾÓÐ0È˻ظ´
¿´¹ýÍù²¡Àú£¬ÓÐÒÉ»óÇë½Ì
ÒѾÓÐ1È˻ظ´
kdl0721
½ð³æ (ÖøÃûдÊÖ)
- Ó¦Öú: 76 (³õÖÐÉú)
- ½ð±Ò: 496.3
- É¢½ð: 69
- ºì»¨: 30
- Ìû×Ó: 1051
- ÔÚÏß: 320Сʱ
- ³æºÅ: 1246356
- ×¢²á: 2011-03-27
- רҵ: ÎÞ»ú·Ç½ðÊô»ù¸´ºÏ²ÄÁÏ
15Â¥2014-04-09 13:39:23
2Â¥2014-03-28 18:46:09
kdl0721
½ð³æ (ÖøÃûдÊÖ)
- Ó¦Öú: 76 (³õÖÐÉú)
- ½ð±Ò: 496.3
- É¢½ð: 69
- ºì»¨: 30
- Ìû×Ó: 1051
- ÔÚÏß: 320Сʱ
- ³æºÅ: 1246356
- ×¢²á: 2011-03-27
- רҵ: ÎÞ»ú·Ç½ðÊô»ù¸´ºÏ²ÄÁÏ
3Â¥2014-03-29 09:36:52
y20063213
ľ³æ (ÕýʽдÊÖ)
- Ó¦Öú: 17 (СѧÉú)
- ½ð±Ò: 1881.1
- É¢½ð: 1
- ºì»¨: 7
- Ìû×Ó: 526
- ÔÚÏß: 668.1Сʱ
- ³æºÅ: 902227
- ×¢²á: 2009-11-13
- רҵ: ºÏ³ÉÒ©Îﻯѧ
4Â¥2014-03-29 10:16:52










»Ø¸´´ËÂ¥